Insulin signaling in skeletal muscle during inflammation and/or immobilisation

Grunow, Julius J.; Gan, Thomas; Lewald, H. Ernest; Martyn, J. A. Jeevendra; Blobner, Manfred; Schaller, Stefan J.

doi:10.1186/s40635-023-00503-9

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Предполагается, что гипертрофированные адипоциты продуцируют адипокины (лептин, остеопоэтин, хемерин, резистин и др. ), активируя клетки иммунной системы (макрофаги М1-типа, тучные клетки, Th1, Th17, Th22-клетки), способные к гиперпродукции провоспалительных цитокинов, таких, как интерфероны, фактор некроза опухолиальфа (ФНО-α), интерлейкин (ИЛ)-1, ИЛ-6, ИЛ-7, ИЛ-8, ИЛ-17 и ИЛ-22, и, таким образом, вызывают местное воспаление [23][24][25][26].…”

Section: результатыunclassified

Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria

Бернс¹,

Sheptulina

Mamutova³

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Recently, two following demographic trends have been clearly observed in the world: population aging and an increase in the prevalence of obesity. In February 2022, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) published the first consensus guidelines for the definition and diagnosis of sarcopenic obesity, which characterizes by a combination of excess adipose tissue with a decrease in muscle mass, muscle strength and impaired muscle function. The purpose of this review is to describe the prevalence, the main etiopathogenetic factors of sarcopenic obesity, as well as currently accepted approaches to the diagnosis of this condition.

show abstract

Section: результатыunclassified

Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria

Бернс¹,

Sheptulina

Mamutova³

et al. 2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

Dietary protein in the ICU in relation to health outcomes

Bear,

Summers,

Chapple

2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of review Critical care nutrition guidelines recommend provision of higher protein doses than recommended in health. These recommendations have been predominately based on lower quality evidence and physiological rationale that greater protein doses may attenuate the significant muscle loss observed in critically ill patients. This review discusses the mechanistic action of protein in the critically ill, details results from recent trials on health outcomes, discusses considerations for interpretation of trial results, and provides an overview of future directions. Recent findings Two recent large clinical trials have investigated different protein doses and the effect on clinical outcome. Important findings revealed potential harm in certain sub-groups of patients. This harm must be balanced with the potential for beneficial effects on muscle mass and physical function given that two recent systematic reviews with meta-analyses demonstrated attenuation of muscle loss with higher protein doses. Utilizing biological markers such as urea: creatinine ratio or urea levels may prove useful in monitoring harm from higher protein doses. Summary Future research should focus on prospectively investigating biological signatures of harm as well as taking into the consideration elements that will likely enhance the effectiveness of protein dose.

show abstract

A scoping review of preclinical intensive care unit-acquired weakness models

Yu,

Song,

Yang

et al. 2024

Front. Physiol.

View full text Add to dashboard Cite

BackgroundAnimal models focusing on neuromuscular outcomes are crucial for understanding the mechanisms of intensive care unit-acquired weakness (ICU-AW) and exploring potential innovative prevention and treatment strategies.AimTo analyse and evaluate preclinical ICU-AW models.MethodsWe manually searched five English and four Chinese databases from 1 January 2002, to 1 February 2024, and reviewed related study references. Full-text publications describing animal models of muscle weakness and atrophy in critical illness were included. Detailed information about model types, animal species, sex, age, induction methods, outcome measures, drawbacks and strengths was extracted from each included study.ResultsA total of 3,451 citations were initially retrieved, with 84 studies included in the final analysis. The most frequently studied animal model included rodents (86.9%), 64.3% of which were male animals. ICU-AW animal models were mostly induced by comprehensive intensive care unit (ICU) interventions (38.1%) and sepsis (51.2%). Most studies focused on limb muscles (66.7%), diaphragm muscles (21.4%) or both (9.5%). Reported outcomes primarily included muscular pathological changes (83.3%), electrophysiological examinations of muscles (57.1%) and animal grip strength (16.6%). However, details such as animal age, mortality data, experimental design, randomisation, blinding, sample size and interventions for the experimental group and/or control group were inadequately reported.ConclusionMany preclinical models are used to study ICU-AW, but the reporting of methodological details is often incomplete. Although current ICU animal models can mimic the characteristics of human ICU-AW, there is no standard model. Future preclinical studies should develop a standard ICU-AW animal model to enhance reproducibility and improve scientific rigor in exploring the mechanisms and potential treatment of ICU-AW.

show abstract

Insulin signaling in skeletal muscle during inflammation and/or immobilisation

Cited by 3 publications

References 41 publications

Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria

Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria

Dietary protein in the ICU in relation to health outcomes

A scoping review of preclinical intensive care unit-acquired weakness models

Contact Info

Product

Resources

About